301 related articles for article (PubMed ID: 29433585)
1. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.
Chen Z; Huang W; Tian T; Zang W; Wang J; Liu Z; Li Z; Lai Y; Jiang Z; Gao J; Shen L
J Hematol Oncol; 2018 Feb; 11(1):20. PubMed ID: 29433585
[TBL] [Abstract][Full Text] [Related]
2. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
3. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
[TBL] [Abstract][Full Text] [Related]
4. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.
Gavine PR; Ren Y; Han L; Lv J; Fan S; Zhang W; Xu W; Liu YJ; Zhang T; Fu H; Yu Y; Wang H; Xu S; Zhou F; Su X; Yin X; Xie L; Wang L; Qing W; Jiao L; Su W; Wang QM
Mol Oncol; 2015 Jan; 9(1):323-33. PubMed ID: 25248999
[TBL] [Abstract][Full Text] [Related]
5. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
[TBL] [Abstract][Full Text] [Related]
6. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
7. EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.
Wang X; Fu R; Hu Y; Du H; Li S; Li Z; Liu Y; Li Q; Zhang L; Ji J
Oncol Rep; 2017 Oct; 38(4):2387-2393. PubMed ID: 28849161
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits.
Corso S; Isella C; Bellomo SE; Apicella M; Durando S; Migliore C; Ughetto S; D'Errico L; Menegon S; Moya-Rull D; Cargnelutti M; Capelôa T; Conticelli D; Giordano J; Venesio T; Balsamo A; Marchiò C; Degiuli M; Reddavid R; Fumagalli U; De Pascale S; Sgroi G; Rausa E; Baiocchi GL; Molfino S; Pietrantonio F; Morano F; Siena S; Sartore-Bianchi A; Bencivenga M; Mengardo V; Rosati R; Marrelli D; Morgagni P; Rausei S; Pallabazzer G; De Simone M; Ribero D; Marsoni S; Sottile A; Medico E; Cassoni P; Sapino A; Pectasides E; Thorner AR; Nag A; Drinan SD; Wollison BM; Bass AJ; Giordano S
Cancer Res; 2019 Nov; 79(22):5884-5896. PubMed ID: 31585941
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
12. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
Chang HR; Park HS; Ahn YZ; Nam S; Jung HR; Park S; Lee SJ; Balch C; Powis G; Ku JL; Kim YH
BMC Cancer; 2016 Mar; 16():200. PubMed ID: 26955870
[TBL] [Abstract][Full Text] [Related]
13. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.
Zhang L; Yang J; Cai J; Song X; Deng J; Huang X; Chen D; Yang M; Wery JP; Li S; Wu A; Li Z; Li Z; Liu Y; Chen Y; Li Q; Ji J
Sci Rep; 2013 Oct; 3():2992. PubMed ID: 24141978
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.
Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X
Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.
Zhang T; Zhang L; Fan S; Zhang M; Fu H; Liu Y; Yin X; Chen H; Xie L; Zhang J; Gavine PR; Gu Y; Ni X; Su X
PLoS One; 2015; 10(7):e0134493. PubMed ID: 26217940
[TBL] [Abstract][Full Text] [Related]
16. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Detection of HER2 Expression in Gastric Cancer by
Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
[TBL] [Abstract][Full Text] [Related]
18. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016
[TBL] [Abstract][Full Text] [Related]
19. Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.
Chen Z; Liu Z; Huang W; Li Z; Zou J; Wang J; Lin X; Li B; Chen D; Hu Y; Ji J; Gao J; Shen L
J Transl Med; 2017 Dec; 15(1):253. PubMed ID: 29237470
[TBL] [Abstract][Full Text] [Related]
20. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
Klinghammer K; Raguse JD; Plath T; Albers AE; Joehrens K; Zakarneh A; Brzezicha B; Wulf-Goldenberg A; Keilholz U; Hoffmann J; Fichtner I
Int J Cancer; 2015 Jun; 136(12):2940-8. PubMed ID: 25404014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
